More than 50 out of the 75 rare diseases’ drugs approved for marketing in China have been incorporated into the catalog of medicines covered by medical insurance.
The National Healthcare Security Administration (NHSA) said this on Tuesday.
To enhance the accessibility and affordability of rare diseases’ drugs, the NHSA has added more qualifying medications to the drug list of medical insurance.
The addition is to optimise the admission procedure and reducing entry barriers.
Efforts have been made to ensure the supply of medications for rare diseases.
As of the end of June 2023, a total of 229,000 designated hospitals and pharmacies nationwide had been stocked with medicines for rare diseases covered by medical insurance.
The NHSA said more eligible medicines for rare diseases would be included in the medical insurance drug list to reduce the burden on patients.
